top of page

NCI-2019-08392

A PHASE 1 STUDY OF ZN-c3 AS A SINGLE AGENT IN SUBJECTS WITH SOLID TUMORS


This study is testing a new medicine called ZN-c3 to see if it's safe for people with solid tumors. They want to see how well the medicine works on its own and if it can help treat cancer.


For more information about the trial, click the link below:

Clinical Trial Site: Sinai


To see all available clinical trials click here.



Recent Posts

See All

NCI-2021-10597

A Phase 1 Open-Label, Dose-Escalation and Cohort Expansion Study of LUNA18 Monotherapy and Combination Therapy in Patients with Locally...

NCI-2022-10927

A Phase I, Multicenter, Open-label, First-in Human, Dose Escalation and Expansion Study of AZD9592 as Monotherapy and in Combination with...

NCT-05753722

An Open-Label Phase 1 Dose-Escalation and Expansion Study Investigating the Safety,Pharmacokinetics, Pharmacodynamics, and Activity of...

Commenti


bottom of page